Working… Menu
Trial record 51 of 144 for:    "Acute promyelocytic leukemia"

Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy (APL0511)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01472107
Recruitment Status : Recruiting
First Posted : November 16, 2011
Last Update Posted : October 23, 2018
Information provided by (Responsible Party):
Gruppo Italiano Malattie EMatologiche dell'Adulto

Brief Summary:
The GIMEMA FOUNDATION promotes an observational (retrospective) study on number and outcome of pregnancy in childbearing age female patients treated with chemotherapy for APL. These patients were enrolled in studies AIDA0493, AIDA2000 and were in CR.

Condition or disease
Acute Promyelocytic Leukemia Pregnancy

Detailed Description:

Acute promielocitic leukaemia (APL) Among all the AML subtypes, APL has the distinction of being the most curable. The median age at diagnosis is 40 years, which is younger than with other AML subtypes. The fact that APL is more common in younger patients increases the likelihood that it may occur during fertile age. The introduction of ATRA and ATO has substantially modified the outcome of APL: in two successive studies 94% of patients achieved CR and the 6-yr OS rates (PETHEMA and GIMEMA) were about 80% 2,3,6.

ATRA is highly effective in APL patients, but adverse effects such as retinoic acid syndrome, arrhythmias, headache, rash, dizziness have been reported. Moreover, retinoids are known to be potent teratogens and increased rates of spontaneous abortion and major fetal abnormalities have been reported 10. Most of the cases reported suggest that ATRA is relatively safe for both mother and fetus when used in the second and third trimesters. By contrast, when it was used in the first trimester, a negative foetal outcome was reported. No data have yet been reported on the outcomes of pregnancies in young patients with APL, occurring during CCR following ATRA-including chemotherapy regimens.

APL therapy AIDA regimen: simultaneous Atra plus IDArubicin (AIDA) combination for induction treatment, followed by 3 courses of intensive chemotherapy as consolidation2.

Consolidation therapy in the AIDA-0493 trial consisted of 3 chemotherapy courses with Ara-C and idarubicin3.

Consolidation treatment in the AIDA-2000 was given according to a risk-adapted strategy as follows: patients with low-/intermediate-risk received the same 3 consolidation courses as in the AIDA-0493 but with omission of cytarabine; patients in the high-risk group received the identical 3 cycles as in the AIDA-0493.

Study rationale This is an observational (retrospective) study on number and outcome of pregnancy in childbearing age female patients treated with chemotherapy for APL. These patients were enrolled in studies studies AIDA0493, AIDA2000 and were in CR.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Observational Study on Number and Outcome of Pregnancy in Childbearing Age Female Patients Treated With Chemotherapy for APL (Studies AIDA 0493, AIDA 2000)
Study Start Date : February 2012
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia

Primary Outcome Measures :
  1. Description of pregnancies [ Time Frame: At 24 monhts from study entry ]
    The primary objective is to describe pregnancies in female patients treated with AIDA0493, AIDA2000 studies.

Secondary Outcome Measures :
  1. Children's health [ Time Frame: at 24 months from study entry ]
    Children's health and follow-up data

  2. Pregnancies evolution [ Time Frame: At 24 months from study entry ]
    Pregnancies evolution and outcome, children health and follow-up data according to AIDA0493 and AIDA2000 treatment strategies

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The patients enrolled in studies AIDA0493, AIDA2000 in CR .

Inclusion Criteria:

  • Patients alive aged between 18 and 50 years
  • Patients with unequivocal diagnosis of APL according to the FAB classification or WHO 2008 diagnostic criteria.

Female in childbearing age treated for APL, enrolled in the studies AIDA0493, AIDA2000 in CR after 2 years of maintenance with the exclusion of those randomized to observation in the AIDA2000, AIDA0493

Exclusion Criteria:

  • Patients aged < 18 and > 50 years;
  • Patients receiving chemotherapy;
  • Concomitant psychiatric disorder that would interfere or prevent the subject from participating in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01472107

Layout table for location contacts
Contact: Paola FAZI, Dr.
Contact: Enrico CREA

Layout table for location information
S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo Recruiting
Alessandria, Italy
Contact: Lorella De Paoli, Dr.         
Principal Investigator: Lorella De Paoli, Dr.         
Sub-Investigator: Flavia Salvi, Dr.         
Azienda Ospedaliera - Nuovo Ospedale "Torrette" Recruiting
Ancona, Italy
Contact: Pietro Leoni         
Principal Investigator: Pietro Leoni, Dr.         
Unità Operativa Ematologia 1 - Università degli Studi di Bari Recruiting
Bari, Italy, 70010
Contact: Giorgina SPECCHIA, Pr.         
Principal Investigator: Giorgina SPECCHIA, Pr.         
Sub-Investigator: Paola CARLUCCIO, Dr.         
Ospedali Riuniti di Bergamo Recruiting
Bergamo, Italy
Contact: Alessandro Rambaldi, Pr.         
Principal Investigator: Alessandro RAMBALDI, Pr.         
Sub-Investigator: Maurizio BUELLI, Dr.         
Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi Recruiting
Bologna, Italy, 40138
Contact: Giovanni MARTINELLI, Pr.   
Principal Investigator: Giovanni MARTINELLI, Pr.         
Sub-Investigator: Cristina PAPAIANNIDIS, Dr.         
Azienda Sanitaria di Bolzano - Ospedale Centrale - Ematologia e Centro TMO Not yet recruiting
Bolzano, Italy
Contact: Vincenzo Cassibba, Dr.         
Principal Investigator: Vincenzo Cassibba, Dr.         
Sub-Investigator: Irene Cavattoni, Dr.         
Sezione di Ematologia e Trapianti Spedali Civili Recruiting
Brescia, Italy, 21125
Contact: Erika BORLENGHI, Dr.   
Principal Investigator: Erika BORLENGHI, Dr.         
Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia Recruiting
Catanzaro, Italy
Contact: Stefano Molica, Dr.         
Principal Investigator: Stefano Molica, Dr.         
Sub-Investigator: Maria Grazia Kropp, Dr.         
Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia Recruiting
Catanzaro, Italy
Contact: Stefano Molica         
Principal Investigator: Stefano Molica         
Sezione di Ematologia C.T.M.O. Istituti Ospitalieri Not yet recruiting
Cremona, Italy
Contact: Francesco Lanza, Pr.         
Principal Investigator: Francesco Lanza, Pr.         
Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna Recruiting
Ferrara, Italy, 44100
Contact: Antonio CUNEO, Pr.         
Principal Investigator: Antonio CUNEO, Pr.         
Sub-Investigator: Maria CICCONE, Dr.         
Policlinico di Careggi, Università delgi studi di Firenze Recruiting
Firenze, Italy
Contact: Alberto BOSI         
Principal Investigator: Alberto BOSI, Dr.         
Clinica Ematologica - DiMI - Università degli Studi di Genova Not yet recruiting
Genova, Italy
Contact: Marco Gobbi, Pr.         
Principal Investigator: Marco Gobbi, Pr.         
Sub-Investigator: Ivana Pierri, Dr.         
Divisione di Ematologia Ospedale "Santa Maria Goretti" Recruiting
Latina, Italy
Contact: Angelo De Blasio, Dr.         
Principal Investigator: Angelo De Blasio, Dr.         
Sub-Investigator: Antonio Centra, Dr.         
Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina Recruiting
Messina, Italy
Contact: Caterina Musolino, Pr.         
Principal Investigator: Caterina Musolino, Pr.         
Sub-Investigator: Demetrio Gerace, Dr.         
Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte" Recruiting
Messina, Italy
Contact: Maura Brugiatelli, Dr.         
Principal Investigator: Maura Brugiatelli, Dr         
Sub-Investigator: Piero Terrizzi, Dr.         
Ospedale Niguarda " Ca Granda" Recruiting
Milano, Italy
Contact: Anna Maria Nosari, Dr.         
Principal Investigator: Anna Maria Nosari, Dr.         
Sub-Investigator: Valentina Mancini, Dr.         
U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele Recruiting
Milano, Italy
Contact: Elena Guggiari, Dr.         
Principal Investigator: Elena Guggiari, Dr.         
Centro Oncologico Modenese - Dipartimento di Oncoematologia Recruiting
Modena, Italy
Contact: Mario Luppi, Dr.         
Principal Investigator: Mario Luppi, Dr.         
Sub-Investigator: Monica Morselli, Dr.         
N. Osp. divisione di Ematologia "S.Gerardo dei Tintori" Recruiting
Monza, Italy
Contact: Monica Fumagalli, Dr.         
Principal Investigator: Monica Fumagalli, Dr.         
Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia Recruiting
Napoli, Italy
Contact: Fabrizio Pane, Pr.         
Principal Investigator: Fabrizio Pane, Pr.         
Sub-Investigator: Giuseppe Cerciello, Dr.         
Ospedale S. Gennaro ASL NA1 Recruiting
Napoli, Italy
Contact: Lucia MASTRULLO, Dr.         
Principal Investigator: Lucia MASTRULLO, Pr.         
Sub-Investigator: Maria Rosaria VILLA, Dr.         
Divisione di Ematologia con trapianto di midollo - A.U. Policlinico "Paolo Giaccone" Not yet recruiting
Palermo, Italy
Contact: Maria Enza Mitra, Dr.         
Principal Investigator: Maria Enza Mitra, Dr.         
Ospedali Riuniti "Villa Sofia-Cervello" Recruiting
Palermo, Italy
Contact: Rosaria Felice, Dr.         
Principal Investigator: Rosaria Felice, Dr.         
Sub-Investigator: Francesco Acquaviva, Dr.         
Cattedra di Ematologia CTMO Università degli Studi di Parma Recruiting
Parma, Italy
Contact: Cecilia CARAMATTI, Dr.         
Principal Investigator: Cecilia CARAMATTI, Dr.         
Sub-Investigator: Elena ROSETTI, Dr.         
Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della MIsericordia Recruiting
Perugia, Italy
Contact: Brunangelo Falini, Pr.         
Principal Investigator: Brunangelo Falini, Pr.         
Istituto di Ematologia- Ospedale San Carlo Recruiting
Potenza, Italy
Contact: Michele PIZZUTI         
Principal Investigator: Michele PIZZUTI, Pr.         
Azienda Ospedaliera Bianchi Melacrino Morelli Recruiting
Reggio Calabria, Italy, 89100
Contact: Francesco NOBILE, Pr.         
Principal Investigator: Francesco Nobile, Pr.         
Sub-Investigator: Caterina Alati, Dr.         
Vulture U.O. di Ematologia - Centro Oncologico Basilicata Recruiting
Rionero in Vulture, Italy
Contact: Pellegrino Musto, Dr.         
Principal Investigator: Pellegrino Musto, Dr.         
Università Cattolica del Sacro Cuore - Policlinico A. Gemelli Recruiting
Roma, Italy, 00168
Contact: Simona SICA, Dr.         
Principal Investigator: Simona SICA, Dr.         
Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia Recruiting
Roma, Italy
Contact: Roberto Foà         
Principal Investigator: Roberto Foà         
Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza Recruiting
S. G. Rotondo, Italy
Contact: Nicola Cascavilla, Dr.         
Principal Investigator: Nicola Cascavilla, Dr.         
Sub-Investigator: Lorella Melillo, Dr.         
U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte" Recruiting
Siena, Italy
Contact: Monica Bocchia, Pr.         
Principal Investigator: Monica Bocchia, Pr.         
Sub-Investigator: Laura Aprile, Dr.         
U.O.C. di Ematolgia - A.O. " SS Annunziata" - P.O. S.G. Moscati Not yet recruiting
Taranto, Italy
Contact: Emilio Iannitto, Dr.         
Principal Investigator: Emilio Iannitto, Dr.         
Sub-Investigator: Maria Rosaria Specchia, Dr.         
SCDO Ematologia 2 AOU S.Giovanni Battista Recruiting
Torino, Italy
Contact: Stefano D'Ardia, Dr.         
Principal Investigator: Stefano D'Ardia, Dr.         
Sub-Investigator: Ernesta Audisio, Dr.         
Clinica Ematologica - Policlinico Universitario Recruiting
Udine, Italy
Contact: Anna Candoni, Dr.         
Principal Investigator: Anna Candoni, Dr.         
Sub-Investigator: Erica Simeone, Dr.         
Ospedale San Bortolo Recruiting
Vicenza, Italy, 36100
Contact: Eros DI BONA, Pr.   
Principal Investigator: Eros DI BONA, Pr.         
Sponsors and Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
Layout table for investigator information
Principal Investigator: Giogina SPECCHIA, Pr. UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari

Additional Information:
Layout table for additonal information
Responsible Party: Gruppo Italiano Malattie EMatologiche dell'Adulto Identifier: NCT01472107     History of Changes
Other Study ID Numbers: APL0511
First Posted: November 16, 2011    Key Record Dates
Last Update Posted: October 23, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Gruppo Italiano Malattie EMatologiche dell'Adulto:
APL female patients
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Promyelocytic, Acute
Neoplasms by Histologic Type
Leukemia, Myeloid, Acute
Leukemia, Myeloid